These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12924538)

  • 1. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
    Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
    Grub S; Delora P; Lüdin E; Duff F; Fletcher CV; Brundage RC; Kline MW; Calles NR; Schwarzwald H; Jorga K
    Clin Pharmacol Ther; 2002 Mar; 71(3):122-30. PubMed ID: 11907486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
    Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
    Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
    Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
    Burger DM; Bergshoeff AS; De Groot R; Gibb D; Walker S; Tréluyer JM; Hoetelmans RM;
    J Pediatr; 2004 Sep; 145(3):403-5. PubMed ID: 15343199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in indinavir exposure over time: a case study in six HIV-1-infected children.
    Fraaij PL; Bergshoeff AS; van Rossum AM; Hartwig NG; Burger DM; de Groot R
    J Antimicrob Chemother; 2003 Oct; 52(4):727-30. PubMed ID: 12917234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].
    de Alarcón A; Viciana P; Lozano F; Vergara A; Pujol E; Barrera A; Pérez-Guzmán E; Colmenero MA; Hernández-Quero J; Márquez M; de la Torre J; Aliaga L; Suárez I; Gutiérrez-Ravé V; Torres-Tortosa M; Marín J; Valdayo MJ; Milla M;
    Enferm Infecc Microbiol Clin; 2003 Dec; 21(10):543-51. PubMed ID: 14642252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
    Villani P; Floridia M; Pirillo MF; Cusato M; Tamburrini E; Cavaliere AF; Guaraldi G; Vanzini C; Molinari A; degli Antoni A; Regazzi M
    Br J Clin Pharmacol; 2006 Sep; 62(3):309-15. PubMed ID: 16934047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
    Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
    HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose ritonavir moderately enhances nelfinavir exposure.
    Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
    Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.